Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interleukin 7 - Revimmune SAS

Drug Profile

Interleukin 7 - Revimmune SAS

Alternative Names: CYT 107; Glycosylated recombinant human interleukin-7 - Cytheris; IL-7; Recombinant human interleukin-7 - Cytheris; rhIL-7; Second-generation CYT 99 007

Latest Information Update: 26 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytheris
  • Developer Cognate BioServices; Cytheris; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Revimmune SAS; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The French National Agency for Research on AIDS and Viral Hepatitis; University Hospital Limoges; Washington University School of Medicine
  • Class Anti-infectives; Antibacterials; Antineoplastics; Antiretrovirals; Antivirals; Cytokines; Interleukins; Recombinant proteins
  • Mechanism of Action Interleukin 7 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Colorectal cancer; HIV infections; Lymphopenia; Nontuberculous mycobacterium infections; Prostate cancer; Sepsis; Urogenital cancer
  • Suspended Idiopathic CD4-positive T-lymphocytopenia
  • Discontinued Bone marrow transplant rejection; Hepatitis B; Hepatitis C; Progressive multifocal leukoencephalopathy

Most Recent Events

  • 09 Apr 2024 Revimmune terminates phase-II IMPULSE-7 clinical trial in Nontuberculous mycobacterium infections (Treatment-experienced) in USA (IM) due to non convincing results (NCT04154826)
  • 25 Jan 2024 Updated efficacy and adverse events data from a phase II trial in Urogenital cancer presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)
  • 20 Oct 2023 Safety and efficacy data from the phase II trial in Urogenital cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top